Trial Profile
A Study Investigating the Impact of Pembrolizumab-Induced Immune Related Adverse Events (irAE) on Survival Outcomes in Advanced Melanoma Patients (irAE) Treated with Pembrolizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 27 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.